Abstract：
:Pharmacokinetics studies were performed in ten patients who received VP-16 by intracarotid infusion at 100-300 mg/m2. VP-16 was analyzed by high-pressure liquid chromatography. ESTRIP and NONLIN were used to characterize VP-16 pharmacokinetics. VP-16 disappeared biphasically, with a t1/2 beta of 6.1 +/- 1.4 h; the total clearance was 26.8 +/- 2.8 ml/min/m2, and the Vss was 8.8 +/- 1.6 l/m2. The pharmacokinetics was not significantly different after administration by the IV route. However, at a lower dosage, less than 140 mg/m2, the half-life appears to be shorter. This may or may not be significant, since VP-16 pharmacokinetics is quite variable and the number of patients studied is relatively small. Overall, the brain and brain tumor do not appear to have any first-pass effect on VP-16 pharmacokinetics.
journal_name
Cancer Chemother Pharmacoljournal_title
Cancer chemotherapy and pharmacologyauthors
Savaraj N,Feun LG,Lu K,Wallace S,Fields WS,Loo TLdoi
10.1007/BF00293995subject
Has Abstractpub_date
1986-01-01 00:00:00pages
292-4issue
3eissn
0344-5704issn
1432-0843journal_volume
16pub_type
杂志文章abstract：:A total of 26 evaluable patients presenting with advanced or metastatic squamous-cell carcinoma of the esophagus were entered in a phase II trial to assess the single-agent activity of etoposide. Etoposide was given at a dose of 200 mg/m2 on 3 consecutive days every 3 weeks. Five patients (19%) achieved a partial resp...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 临床试验,杂志文章
doi：10.1007/BF00685952
更新日期：1992-01-01 00:00:00
abstract：PURPOSE:To evaluate the safety and efficacy of the combination of cisplatin on day 1 and docetaxel on days 1, 8 and 15 every 4 weeks for the treatment of previously untreated patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:A group of 38 patients with advanced or metastatic NSCLC who had not rece...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 临床试验,杂志文章
doi：10.1007/s00280-004-0810-5
更新日期：2004-08-01 00:00:00
abstract：PURPOSE:To determine the efficacy and safety of the combination therapy with docetaxel and cisplatin (CDDP) at low doses in elderly patients with advanced NSCLC. PATIENTS AND METHODS:A total of 42 patients aged > or =70 years with previously untreated advanced NSCLC received docetaxel 75 mg/m(2) plus CDDP 50 mg/m(2) o...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章,多中心研究
doi：10.1007/s00280-008-0749-z
更新日期：2009-02-01 00:00:00
abstract：:Bizelesin (U-77779) is a highly potent bis-alkylating antitumor agent that is effective against several tumor systems in vitro and in vivo. V79 cells that were 125- to 250-fold resistant to bizelesin developed after constant exposure to gradually increasing concentrations of the drug. Resistant cells exhibited a multi...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/BF00686110
更新日期：1994-01-01 00:00:00
abstract：:The effect of selenite coadministration on the toxicity and antitumor activity of repeated treatment with high doses of cis-diamminedichloroplatinum (cis-DDP) was examined in mice. Sodium selenite was injected s.c. into separate abdominal sites of mice together with cis-DDP at a molar ratio of 1:3.5 (selenite to cis-D...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/BF00685594
更新日期：1992-01-01 00:00:00
abstract：PURPOSE:Chemosensitizers such as cyclosporin A can increase intracellular accumulation of chemotherapeutic agents such as Adriamycin in certain multidrug-resistant (MDR) cell lines with overexpression of P-glycoprotein. It is likely that, when combined with cyclosporin A, hyperthermia could increase membrane permeabili...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s002800050033
更新日期：2000-01-01 00:00:00
abstract：:GR63178A is the second pentacyclic pyrroloquinone to enter clinical trials as an anticancer drug. We developed a reversed-phase, gradient-elution high-performance liquid chromatography (HPLC) method along with a Bond Elut C2 mini-column sample-preparation technique for the analysis of GR63178A, its 9-hydroxy-metabolit...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/BF00684952
更新日期：1991-01-01 00:00:00
abstract：PURPOSE:RO5323441 is a humanized anti-placental growth factor (PlGF) monoclonal antibody that has shown preclinical activity in several cancer models. The objective of this analysis is to examine the pharmacokinetic (PK) results from four Phase I studies that have been conducted with RO5323441 (n = 61) and to report an...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章,多中心研究
doi：10.1007/s00280-017-3242-8
更新日期：2017-04-01 00:00:00
abstract：PURPOSE:Chemotherapy dosing in neonates represents a major clinical challenge because of a lack of clinical pharmacology information in this patient population. In this study, we investigate the use of cisplatin dose adaptation based on therapeutic drug monitoring in a 2-week-old neonate with localized hepatoblastoma. ...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-018-3625-5
更新日期：2018-08-01 00:00:00
abstract：BACKGROUND:As tumors evolve, they upregulate glucose metabolism while also encountering intermittent periods of glucose deprivation. Here, we investigate mechanisms by which pancreatic cancer cells respond to therapeutic (2-deoxy-D-glucose, 2-DG) and physiologic (glucose starvation, GS) forms of glucose restriction. M...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-013-2358-8
更新日期：2014-02-01 00:00:00
abstract：:This report describes the physicochemical and pharmacokinetic parameters of seven chlorambucil esters, which were compared with those of chlorambucil. These esters were designed as chlorambucil prodrugs to increase the brain penetration and concentration vs time profile of chlorambucil within the CNS for potential tre...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/BF00686229
更新日期：1990-01-01 00:00:00
abstract：:The in vitro effect of the dextroisomer r-verapamil on blast cells derived from patients with acute myelogenous leukemia (AML) was studied. R-verapamil caused a dose-dependent inhibition of AML blast proliferation in the presence of stem-cell factor, leukemia inhibitory factor, interleukin 4, interleukin 6, and interl...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/BF00685631
更新日期：1995-01-01 00:00:00
abstract：:Our previous randomised trial in patients with advanced ovarian cancer indicated a significant response and survival advantage for those receiving high-dose (100 mg/m2) as compared with low-dose (50 mg/m2) cisplatin in combination with cyclophosphamide (750 mg/m2). However, this was accompanied by more toxicity; perip...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 临床试验,杂志文章,随机对照试验
doi：10.1007/s002800050723
更新日期：1998-01-01 00:00:00
abstract：:Pancreatic cancer is the fourth leading cause of cancer-related deaths in the USA, with a 5-year survival rate of 6 %. Anti-hyperglycemic treatments for type 2 diabetes mellitus that induce hyperinsulinemia (i.e., sulfonylureas) are thought to increase cancer risk, whereas treatments that lower insulin resistance and ...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章,评审
doi：10.1007/s00280-015-2948-8
更新日期：2016-02-01 00:00:00
abstract：BACKGROUND:Hemolytic anemia has been noted during treatment with a variety of chemotherapeutic agents. We observed mild compensated hemolytic anemia in a patient receiving capecitabine during a randomized, controlled trial of adjuvant therapy. In order to investigate the hypothesis that hemolysis is the underlying caus...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章,随机对照试验
doi：10.1007/s00280-005-1011-6
更新日期：2005-12-01 00:00:00
abstract：PURPOSE:Tetrandrine (Tet), a bis-benzylisoquinoline alkaloid that was isolated from the dried root of Hang-Fang-Chi (Stephania tetrandra S. Moore), is well known as processing a marked antitumor effect in vitro and in vivo. The aim of this study was to assess the interaction between tetrandrine and chemotherapeutic age...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-007-0416-9
更新日期：2007-10-01 00:00:00
abstract：PURPOSE:Amsalog, a derivative of 9-aminoacridine, is an inhibitor of topoisomerase II. Early studies of intravenous amsalog administered either once weekly, or daily for 3 days repeated every 3 weeks, showed that myelosuppression is the dose-limiting toxicity (DLT). Phase II studies showed only limited activity in brea...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 临床试验,杂志文章
doi：10.1007/s002800000216
更新日期：2001-04-01 00:00:00
abstract：PURPOSE:Cisplatin and radiation therapy remain the current standard for treating locally advanced SCCHN. Novel treatment approaches are needed, especially in patients with human papilloma virus (HPV)-negative disease who have worse outcomes despite multimodality therapy. METHODS:Using our institutional review board ap...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-014-2584-8
更新日期：2014-11-01 00:00:00
abstract：:Twenty patients with bladder cancer (T1, 3 patients; T2, 6 patients; T3, 8 patients; T4a, 3 patients) were preoperatively treated with intra-arterial doxorubicin chemotherapy in combination with low-dose irradiation. The originally scheduled operations were as follows: total cystectomy in 16 patients (T1 + cis, 1 pati...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/BF00262477
更新日期：1987-01-01 00:00:00
abstract：:The ubiquitin-proteasome system (UPS) is an important system that regulates the balance of intracellular proteins, and it is involved in the regulation of multiple vital biological processes. The approval of bortezomib for relapsed and refractory multiple myeloma has proven that agents targeting the UPS have the poten...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章,评审
doi：10.1007/s00280-018-3541-8
更新日期：2018-05-01 00:00:00
abstract：PURPOSE:miRNAs are implicated in drug resistance of multiple cancers including non-small cell lung cancer (NSCLC), highlighting the potential of miRNAs as chemoresistance regulators in cancer treatment. This study aims to explore the relationship between miR-181c and chemoresistance of NSCLC cells. METHODS:qRT-PCR was...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-017-3435-1
更新日期：2017-11-01 00:00:00
abstract：:The novel isocoumarin 2-(8-hydroxy-6-methoxy-1-oxo-1 H-2-benzopyran-3-yl) propionic acid (NM-3) has completed phase I clinical evaluation as an orally bioavailable angiogenesis inhibitor. NM-3 directly kills both endothelial and tumor cells in vitro at low mM concentrations and is effective in the treatment of diverse...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-005-1013-4
更新日期：2005-12-01 00:00:00
abstract：:A combination of carboplatin, vincristine, methotrexate and bleomycin (COMB) was given to 29 patients with locally advanced, metastatic or recurrent cervical carcinoma. A total of 85 cycles of chemotherapy were given, with half of the patients receiving greater than 3 cycles. Both the response rate (32.1%) and the med...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/BF00685165
更新日期：1991-01-01 00:00:00
abstract：:O-6-methylguanine (O6-mG), a guanine analog recently shown to be a potent inhibitor of alkylguanine-DNA alkyltransferase, has been found to potentiate the antitumor activity of nitrosoureas, in particular, carmustine (BCNU), in resistant cell lines (HT-29 mer+) and is targeted for development as a modulating agent wit...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/BF00686216
更新日期：1993-01-01 00:00:00
abstract：BACKGROUND:Veliparib (ABT-888) is an oral PARP inhibitor expected to increase gemcitabine activity. This phase I determined the maximal tolerable dose (MTD), dose-limiting toxicities (DLT), antitumor activity, pharmacokinetics (PK), and pharmacodynamics (PD) of veliparib combined with gemcitabine. METHODS:Patients wit...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章,多中心研究
doi：10.1007/s00280-017-3409-3
更新日期：2017-09-01 00:00:00
abstract：PURPOSE:The safety and efficacy of oral metronomic low-dose treosulfan chemotherapy in combination with the cyclooxygenase-2 (COX-2) inhibitor rofecoxib as a compound with antiangiogenic potential, a therapeutic regimen optimally targeting endothelial cells instead of tumor cells, were assessed in pretreated advanced m...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 临床试验,杂志文章
doi：10.1007/s00280-003-0678-9
更新日期：2003-11-01 00:00:00
abstract：:Ankinomycin is a new antitumor antibiotic found in the culture broth of Streptomyces sp. SF2587. Ankinomycin showed marked cytotoxicity and antitumor activity against some murine leukemias, but the activity against murine solid tumors was rather weak because of its strong acute toxicity. We synthesized ankinomycin acy...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/BF00685831
更新日期：1993-01-01 00:00:00
abstract：PURPOSE:Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma. Results of pharmacokinetic studies indicate that the optimal schedule of ifosfamide should be repeated doses over several days. With the development of 5-day infusion devices, we developed and evaluated a 5-day infusion regimen of ifos...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 临床试验,杂志文章
doi：10.1007/s00280-009-1054-1
更新日期：2010-02-01 00:00:00
abstract：PURPOSE:To develop more potent procaspase-3 activator, 7 novel derivatives of PAC-1 were synthesized and evaluated. Among them, SM-1 stood out for its promising activity and good pharmacokinetics properties. The purpose of this study is to elucidate the pharmacological mechanism of SM-1 and evaluate its efficacy and to...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章
doi：10.1007/s00280-016-3115-6
更新日期：2016-09-01 00:00:00
abstract：:The full-scale commercial appearance of antibiotics in the 1950s caused a shift in the nature of lethal diseases from infectious and acute to noninfectious and chronic. In this situation, biological response modifiers (BRMs), which are not based on selective toxicity, could be expected to be useful. Several types of B...
journal_title：Cancer chemotherapy and pharmacology
pub_type： 杂志文章,评审
doi：10.1007/s00280-003-0590-3
更新日期：2003-07-01 00:00:00
